CL2018001631A1 - Compuestos de dihidroquinolinsulfonamida de alquilo - Google Patents
Compuestos de dihidroquinolinsulfonamida de alquiloInfo
- Publication number
- CL2018001631A1 CL2018001631A1 CL2018001631A CL2018001631A CL2018001631A1 CL 2018001631 A1 CL2018001631 A1 CL 2018001631A1 CL 2018001631 A CL2018001631 A CL 2018001631A CL 2018001631 A CL2018001631 A CL 2018001631A CL 2018001631 A1 CL2018001631 A1 CL 2018001631A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- dihydroquinolinsulfonamide
- alkyl
- sodium channels
- picazón
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000000217 alkyl group Chemical group 0.000 title 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 2
- 102000018674 Sodium Channels Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003385 sodium Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE FÓRMULA I, Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, QUE SON INHIBIDORES DE LOS CANALES DE SODIO ACTIVADOS POR VOLTAJE, EN PARTICULAR NAV1.7. LOS COMPUESTOS SON ÚTILES PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA ACTIVIDAD DE LOS CANALES DE SODIO TALES COMO TRASTORNOS DEL DOLOR, TOS Y PICAZÓN. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN COMPUESTOS DE LA PRESENTE INVENCIÓN.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269518P | 2015-12-18 | 2015-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001631A1 true CL2018001631A1 (es) | 2018-09-28 |
Family
ID=57758767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001631A CL2018001631A1 (es) | 2015-12-18 | 2018-06-15 | Compuestos de dihidroquinolinsulfonamida de alquilo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10383866B2 (es) |
| EP (1) | EP3390392B1 (es) |
| JP (1) | JP6903663B2 (es) |
| KR (1) | KR102804113B1 (es) |
| CN (2) | CN119119017A (es) |
| AU (1) | AU2016369652B2 (es) |
| CA (1) | CA3008484C (es) |
| CL (1) | CL2018001631A1 (es) |
| CO (1) | CO2018007436A2 (es) |
| CR (1) | CR20180368A (es) |
| EA (1) | EA038286B1 (es) |
| IL (1) | IL259918B (es) |
| MA (1) | MA44065A (es) |
| MX (1) | MX377032B (es) |
| MY (1) | MY197595A (es) |
| NZ (1) | NZ743377A (es) |
| PE (1) | PE20181328A1 (es) |
| PH (1) | PH12018501285A1 (es) |
| SG (1) | SG11201805066RA (es) |
| TN (1) | TN2018000214A1 (es) |
| UA (1) | UA122913C2 (es) |
| WO (1) | WO2017106871A1 (es) |
| ZA (1) | ZA201804033B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| ES3023366T3 (en) * | 2020-06-10 | 2025-05-30 | Amgen Inc | Heteroalkyl dihydroquinoline sulfonamide compounds |
| JP7739051B2 (ja) * | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| WO2023016562A1 (zh) * | 2021-08-12 | 2023-02-16 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AU2012296529A1 (en) * | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| EP2788332A1 (en) * | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9776995B2 (en) * | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-12-19 MX MX2018007432A patent/MX377032B/es active IP Right Grant
- 2016-12-19 EP EP16823447.4A patent/EP3390392B1/en active Active
- 2016-12-19 JP JP2018531483A patent/JP6903663B2/ja active Active
- 2016-12-19 KR KR1020187019086A patent/KR102804113B1/ko active Active
- 2016-12-19 CA CA3008484A patent/CA3008484C/en active Active
- 2016-12-19 AU AU2016369652A patent/AU2016369652B2/en active Active
- 2016-12-19 NZ NZ743377A patent/NZ743377A/en unknown
- 2016-12-19 CN CN202411119481.8A patent/CN119119017A/zh active Pending
- 2016-12-19 CN CN201680074274.2A patent/CN108602804B/zh active Active
- 2016-12-19 WO PCT/US2016/067617 patent/WO2017106871A1/en not_active Ceased
- 2016-12-19 EA EA201891319A patent/EA038286B1/ru unknown
- 2016-12-19 UA UAA201806895A patent/UA122913C2/uk unknown
- 2016-12-19 PE PE2018001136A patent/PE20181328A1/es unknown
- 2016-12-19 CR CR20180368A patent/CR20180368A/es unknown
- 2016-12-19 US US16/062,606 patent/US10383866B2/en active Active
- 2016-12-19 SG SG11201805066RA patent/SG11201805066RA/en unknown
- 2016-12-19 MY MYPI2018000912A patent/MY197595A/en unknown
- 2016-12-19 MA MA044065A patent/MA44065A/fr unknown
- 2016-12-19 TN TNP/2018/000214A patent/TN2018000214A1/en unknown
-
2018
- 2018-06-10 IL IL259918A patent/IL259918B/en active IP Right Grant
- 2018-06-14 PH PH12018501285A patent/PH12018501285A1/en unknown
- 2018-06-15 CL CL2018001631A patent/CL2018001631A1/es unknown
- 2018-06-15 ZA ZA2018/04033A patent/ZA201804033B/en unknown
- 2018-07-17 CO CONC2018/0007436A patent/CO2018007436A2/es unknown
-
2019
- 2019-07-12 US US16/510,816 patent/US20200009129A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| SV2016005311A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| ECSP19066721A (es) | Inhibidores duales de magl y faah | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| CL2017002957A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| MX2018004868A (es) | Derivados de la pirrolidina. | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| MX2018005100A (es) | Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos. | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| CU20140107A7 (es) | Derivados macrocíclicos para el tratamiento de enfermedades |